(CIX: WRAL30)  1,017.74  up arrow+1.44  (0.14 %)  Updated: 04:30 PM EST, Feb 10 2016
(NQ: Apple)  94.27  down arrow-0.72  (-0.76 %)  Updated: 04:30 PM EST, Feb 10 2016
(NY: QUINTILES)  58.35  up arrow+1.65  (2.91 %)  Updated: 04:15 PM EST, Feb 10 2016
(OP: BASF SE)  64.65  down arrow-0.39  (-0.61 %)  Updated: 03:51 PM EST, Feb 10 2016
(NQ: BioCryst)  1.80  down arrow-0.09  (-4.76 %)  Updated: 04:30 PM EST, Feb 10 2016
(NQ: BioDelivery)  3.49  down arrow-0.08  (-2.24 %)  Updated: 04:30 PM EST, Feb 10 2016
(NQ: CEMP)  16.60  up arrow+0.11  (0.67 %)  Updated: 04:30 PM EST, Feb 10 2016
(NQ: Cisco)  22.51  down arrow-0.14  (-0.62 %)  Updated: 04:30 PM EST, Feb 10 2016
(NQ: Cree)  29.30  down arrow-0.06  (-0.2 %)  Updated: 04:30 PM EST, Feb 10 2016
(NQ: DARA)  0.88    (0 %)  Updated: 08:10 PM EST, Dec 04 2015
(NY: EMC)  24.55  up arrow+0.38  (1.57 %)  Updated: 04:15 PM EST, Feb 10 2016
(NQ: Extreme Networks)  2.48  down arrow-0.04  (-1.59 %)  Updated: 04:30 PM EST, Feb 10 2016
(NQ: Facebook)  101.00  up arrow+1.46  (1.47 %)  Updated: 04:30 PM EST, Feb 10 2016
(NY: GLAXOSMITHKLINE)  39.13  down arrow-0.21  (-0.53 %)  Updated: 04:15 PM EST, Feb 10 2016
(NQ: Alphabet)  684.12  up arrow+6.01  (0.89 %)  Updated: 04:30 PM EST, Feb 10 2016
(NY: IBM)  120.19  down arrow-3.88  (-3.13 %)  Updated: 04:15 PM EST, Feb 10 2016
(NY: LH)  104.59  up arrow+2.06  (2.01 %)  Updated: 04:15 PM EST, Feb 10 2016
(OP: Lenovo Group)  16.64  up arrow+0.14  (0.85 %)  Updated: 03:56 PM EST, Feb 10 2016
(NY: MRK)  49.53  up arrow+0.37  (0.75 %)  Updated: 04:15 PM EST, Feb 10 2016
(NQ: Microsoft)  49.71  up arrow+0.43  (0.87 %)  Updated: 04:30 PM EST, Feb 10 2016
(NQ: NetApp)  22.38  up arrow+0.34  (1.54 %)  Updated: 04:30 PM EST, Feb 10 2016
(NY: NOVARTIS AG)  72.99  up arrow+0.37  (0.51 %)  Updated: 04:15 PM EST, Feb 10 2016
(OP: Novozymes A/S)  41.32  up arrow+0.32  (0.77 %)  Updated: 03:59 PM EST, Feb 10 2016
(NY: Pfizer)  29.49  up arrow+0.39  (1.34 %)  Updated: 04:15 PM EST, Feb 10 2016
(NQ: Pozen)  5.94    (0 %)  Updated: 08:10 PM EST, Feb 05 2016
(NY: Red Hat)  63.54  up arrow+1.94  (3.15 %)  Updated: 04:15 PM EST, Feb 10 2016
(NQ: BBRY)  6.64  down arrow-0.08  (-1.19 %)  Updated: 04:30 PM EST, Feb 10 2016
(NQ: Salix)  172.81    (0 %)  Updated: 08:10 PM EDT, Apr 01 2015
(NQ: SQI)  12.03  down arrow-0.02  (-0.17 %)  Updated: 04:30 PM EST, Feb 10 2016

Posts tagged “GSK”

Updated February 3

GSK posts $616M loss for 4th quarter; CEO sees 'substantial progress'

GSK in Zebulon  British-based drugmaker GlaxoSmithKline (NYSE: GSK) posted a loss of $616 million for the fourth quarter of 2015 - compared with a profit of over $1 for the same period a year earlier- as the company moved to integrate new businesses. Its top exec says GSK is making progress.

February 2

Premium Lock GSK expands cancer drug development deal with Adaptimmune

Cancer research  GlaxoSmithKline, which sold its oncology portfolio to Novartis in 2014, is expanding a development deal with Adaptimmune to explore possible cancer treatments. GSK announces earnings on Wednesday.

February 2

Premium Lock GSK invests in another startup fund along with J&J

GSK's HQ in London             GlaxoSmithKline, which is under growing investor pressure to improve its financials, is investing alongside Johnson & Johnson in another startup fund. For the second time in a week, GSK moves to back new and emerging ventures in hopes of driving future growth.

Updated January 26

Sprint cutting jobs; Lenovo security bug; GSK investor pressure; Arista counter-sues Cisco

Bulldog In today's Bulldog wrapup of technology and life science news: Sprint is cutting jobs and closing six call centers; another security problem for Lenovo; investor pressure mounts for change at GSK; and Arista counter-sues Cisco.

Updated January 25

Lenovo adware suits; Google back taxes; GSK $15M in new fund; Novozymes poultry product

Bulldog In today's Bulldog wrapup of technology and life science news: Lenovo fights lawsuits over adware; Google pays back taxes in U.K.; GSK puts $15 million in new university drug development fund; and Novozymes launches a poultry product with French partner.

Updated January 21

Charlotte woman among 5 charged with scheme to steal GSK secrets

GSK in Zebulon  A woman who is a twin sister of a former scientists at GSK is charged conspiracy to steal secrets from the drug giant. The sister, who was fired recently by GSK, also is charged along with three others.

January 21

GSK, Pfizer, Merck join drug industry-government alliance to fight superbugs

Infections Drug giants GlaxoSmithKline, Pfizer and Merck, all of which have a big presence in North Carolina, are teaming with dozens of other companies and governments to form an alliance to fight "superbugs."

December 23, 2015

Premium Lock New GSK drug's price criticized; Google expands in Tennessee; 'Dotcom' faces extradition; Turing seeks CEO

Bulldog In today's Bulldog wrapup of technology and life science news: An independent group is criticizing the price of GSK's new asthma drug; Google to invfest $600 million in Tennessee data center expansion; Kim Dotcom faces extradition to the U.S.; and drug company Turing is looking for a new CEO to replace Martin Shkreli.

December 18, 2015

Premium Lock GSK buying HIV drug pipeline from Bristol-Myers Squibb in $1.46B deal

GSK's HQ in London             GlaxoSmithKline is boosting its own efforts to fight AIDS by agreeing to buy the HIV drug pipeline of Bristol-Myers Squibb in a deal valued at as much as $1.46 billion. In May, GSK said it would invest $20 million in a deal with UNC-Chapel Hill to develop an AIDS cure.

December 17, 2015

Premium Lock GSK arthritis drug advances; Washington sues tech support firm; streaming music fees go up; FDA OKs cheaper diabetes drug

Bulldog In today's Bulldog wrapup of technology and life science news: A new arthritis drug from GSK moves toward regulatory approval; the state of Washington is suing tech support firm iYogi, alleging it scams customers; streaming music fees are going up; and the FDA approves a cheaper diabetes drug.

December 3, 2015

Premium Lock GSK's $440M antibody deal; INC shareholders sell; Bioventus, PowerSecure make buys; Dara BioSciences merger advances

Bulldog In today's wrapup of technology and life science news: GSK strikes investment deal for antibodies; INC's big shareholders sell; Bioventus and PowerSecure make acquisitions; and Dara Biosciences moves ahead with merger.

Updated November 24, 2015

Premium Lock GSK inks $100 million deal with Idera Pharmaceuticals

GSK   GSK has struck a development agreement with Idera Pharmaceuticals, Inc., which develops drugs for patients with renal disease. The deal comes with an up-front payment of $2.5 million to Idera, and is worth as much as $100 million.

November 20, 2015

Premium Lock 1 in 3 two-year-olds in the United States have not received all recommended childhood vaccines, study finds

RTI International One-third of children did not receive all recommended vaccinations by 24 months of age. Western states had the lowest completion rates, Southern states had the highest.

Tags: Fiber, GSK, RTI
November 19, 2015

Premium Lock GSK grants $400,000 to ten Triangle nonprofits

GSK   GSK today announced the ten Triangle-area nonprofits that will receive $40,000 each to build healthy communities by tackling employment, housing, literacy, and other pressing community health challenges.

Tags: GSK
November 5, 2015

Premium Lock Glaxo wins US approval for drug to treat severe asthma

GSK   The FDA cleared an injectable asthma drug made by GlaxoSmithKline on Wednesday. The drug, Nucala, joins four other respitory medicines from GSK.

Tags: GSK
October 29, 2015

Premium Lock GSK sales increase, beats estimates, but profits delcine

GSK GlaxoSmithKline, one of the Research Triangle's largest employers, saw increased sales in the third quarter that beat analysts estimates in the thrid quarter despite declining profits. It reported sales of $9.4 billion in the quarter, up 11 percent over the same period last year, but profits declined to $2.6 billion, a 5 percent drop.

September 9, 2015

Premium Lock Another GSK setback: Lung drug doesn't extend lives in study

GSK in Zebulon  A closely watched study of GlaxoSmithKline plc's Breo Ellipta respiratory treatment failed to prove that it extends patients' lives, denying the drugmaker a much-needed marketing edge in its most lucrative - but declining - medicine category.

August 21, 2015

Premium Lock Novartis buying GSK multiple sclerosis drug for $1B plus royalties

GSK's HQ in London             GlaxoSmithKline has struck another major deal with Novartis. This time the drug giants are teaming up for a deal worth more than $1 billion plus royalties to GSK for an experimental multiple sclerosis drug. The deal will help GSK focus on other priorities, a top executive says.

August 17, 2015

Premium Lock Bezos disputes critical Amazon story; GSK plant reopens; Lenovo's new storage move; report links AT&T, NSA

Bulldog In today's Bulldog wrapup of technology and life science news: Jeff Bezos disputes a New York Times story critical of the company's work environment; GSK reopens its plant in Zebulon; Lenovo launches a new storage product; and a New York Times report links AT&T with the NSA.

August 17, 2015

Premium Lock GSK plans to reopen Zebulon plant Monday, says drugs are safe

GSK in Zebulon  GlaxoSmithKline plans to reopen its Zebulon site Monday after bacteria that causes Legionnaires' disease was found in the cooling towers.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith